Centenary Institute delivers Tour de Cure milestone

The discovery, led by Dr Charles (Chuck) Bailey, Head of the Centenary Institute’s Centre for Rare Diseases and Gene Therapy, identified a previously unknown gateway into human cells, a receptor called AAVR2. The finding could pave the way for safer and more effective gene therapies for a range of serious conditions.

“I’m thrilled and deeply honoured that my team’s work marks Tour de Cure’s 200^th funded breakthrough,” said Dr Bailey.

“Funding from organisations like Tour de Cure is critical for researchers to pursue bold, early-stage ideas that traditional larger government grants often overlook. Not all research results in a formal ‘breakthrough’, but every rigorously conducted project adds valuable knowledge. Each study brings us closer to understanding cancer’s causes, improving prevention and refining treatment.”

The 200th achievement was celebrated at a reception at Government House attended by Her Excellency the Honourable Margaret Beazley AC KC, Governor of New South Wales, Tour de Cure and Dr Bailey.

Read more about Tour de Cure’s celebration of this significant research milestone here.